6.
Nucci M, Anaissie E
. Fusarium infections in immunocompromised patients. Clin Microbiol Rev. 2007; 20(4):695-704.
PMC: 2176050.
DOI: 10.1128/CMR.00014-07.
View
7.
Nucci M, Marr K, Vehreschild M, De Souza C, Velasco E, Cappellano P
. Improvement in the outcome of invasive fusariosis in the last decade. Clin Microbiol Infect. 2013; 20(6):580-5.
DOI: 10.1111/1469-0691.12409.
View
8.
Campo M, Lewis R, Kontoyiannis D
. Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998-2009. J Infect. 2010; 60(5):331-7.
DOI: 10.1016/j.jinf.2010.01.010.
View
9.
Benish M, Elitzur S, Arad-Cohen N, Barg A, Ben-Harosh M, Bielorai B
. Invasive Fusariosis in Pediatric Hematology/Oncology and Stem Cell Transplant Patients: A Report from the Israeli Society of Pediatric Hematology-Oncology. J Fungi (Basel). 2022; 8(4).
PMC: 9030963.
DOI: 10.3390/jof8040387.
View
10.
Soler-Palacin P, Frick M, Martin-Nalda A, Lanaspa M, Pou L, Rosello E
. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study. J Antimicrob Chemother. 2011; 67(3):700-6.
DOI: 10.1093/jac/dkr517.
View
11.
Volpe Arnoni M, Paula C, Auler M, Simoes C, Nakano S, Szeszs M
. Infections Caused by Fusarium Species in Pediatric Cancer Patients and Review of Published Literature. Mycopathologia. 2018; 183(6):941-949.
DOI: 10.1007/s11046-018-0257-6.
View
12.
Schwartz K, Sheffield H, Richardson S, Sung L, Morris S
. Invasive Fusariosis: A Single Pediatric Center 15-Year Experience. J Pediatric Infect Dis Soc. 2015; 4(2):163-70.
DOI: 10.1093/jpids/pit080.
View
13.
de Moraes Costa Carlesse F, de Araujo O, Marques L, da Silva D, Senerchia A, Petrilli A
. A pharmacokinetic model for voriconazole in a highly diversified population of children and adolescents with cancer. Mycoses. 2019; 62(4):399-404.
DOI: 10.1111/myc.12899.
View
14.
Nobrega de Almeida J, Francisco E, Holguin Ruiz A, Cuellar L, Aquino V, Mendes A
. Epidemiology, clinical aspects, outcomes and prognostic factors associated with Trichosporon fungaemia: results of an international multicentre study carried out at 23 medical centres. J Antimicrob Chemother. 2021; 76(7):1907-1915.
DOI: 10.1093/jac/dkab085.
View
15.
Warny M, Helby J, Nordestgaard B, Birgens H, Bojesen S
. Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study. PLoS Med. 2018; 15(11):e1002685.
PMC: 6211632.
DOI: 10.1371/journal.pmed.1002685.
View
16.
Litvinov N, da Silva M, van der Heijden I, Graca M, Oliveira L, Fu L
. An outbreak of invasive fusariosis in a children's cancer hospital. Clin Microbiol Infect. 2015; 21(3):268.e1-7.
DOI: 10.1016/j.cmi.2014.09.004.
View
17.
Lauten M, Attarbaschi A, Cario G, Doring M, Moser O, Mucke U
. Invasive mold disease of the central nervous system in children and adolescents with cancer or undergoing hematopoietic stem cell transplantation: Analysis of 29 contemporary patients. Pediatr Blood Cancer. 2019; 66(8):e27806.
DOI: 10.1002/pbc.27806.
View
18.
Ruijters V, Oosterom N, van der Perk M, Wolfs T, Meijer A, van den Heuvel-Eibrink M
. Clinical Characteristics of Invasive Fungal Infections in Pediatric Oncology Patients With Solid Tumors. J Pediatr Hematol Oncol. 2020; 43(3):e408-e413.
DOI: 10.1097/MPH.0000000000001761.
View
19.
Horn D, Freifeld A, Schuster M, Azie N, Franks B, Kauffman C
. Treatment and outcomes of invasive fusariosis: review of 65 cases from the PATH Alliance(®) registry. Mycoses. 2014; 57(11):652-8.
DOI: 10.1111/myc.12212.
View
20.
Koc B, Tekkesin F, Yildirim U, Caki Kilic S
. Use of granulocyte transfusion in early period in life-threatening infections of pediatric hematology and oncology patients: A single-center experience. Transfus Apher Sci. 2021; 60(4):103134.
DOI: 10.1016/j.transci.2021.103134.
View